O	0	10	Randomized
O	11	18	control
O	19	24	trial
O	24	25	:
O	26	36	evaluating
B-intervention	37	45	aluminum
I-intervention	45	46	-
I-intervention	46	51	based
I-intervention	52	66	antiperspirant
O	67	70	use
O	70	71	,
O	72	78	axilla
O	79	83	skin
O	84	92	toxicity
O	92	93	,
O	94	97	and
O	98	106	reported
O	107	114	quality
O	115	117	of
O	118	122	life
O	123	125	in
B-eligibility	126	131	women
I-eligibility	132	141	receiving
I-eligibility	142	150	external
I-eligibility	151	155	beam
I-eligibility	156	168	radiotherapy
I-eligibility	169	172	for
I-eligibility	173	182	treatment
I-eligibility	183	185	of
I-eligibility	186	191	Stage
I-eligibility	192	193	0
I-eligibility	193	194	,
I-eligibility	195	196	I
I-eligibility	196	197	,
I-eligibility	198	201	and
I-eligibility	202	204	II
I-eligibility	205	211	breast
I-eligibility	212	218	cancer
O	218	219	.

O	220	228	Standard
O	229	233	skin
O	234	238	care
O	239	251	instructions
O	252	261	regarding
O	262	265	the
O	266	269	use
O	270	272	of
O	273	288	antiperspirants
O	289	295	during
O	296	308	radiotherapy
O	309	311	to
O	312	315	the
O	316	322	breast
O	323	329	varies
O	330	336	across
B-location	337	342	North
I-location	343	350	America
O	350	351	.

O	352	357	Women
O	358	362	have
O	363	374	articulated
O	375	379	that
O	380	384	when
O	385	395	instructed
O	396	398	to
O	399	402	not
O	403	406	use
O	407	421	antiperspirant
O	421	422	,
O	423	426	the
O	427	436	potential
O	437	440	for
O	441	445	body
O	446	450	odor
O	451	453	is
O	454	465	distressing
O	465	466	.

O	467	477	Historical
O	478	487	practices
O	488	491	and
O	492	502	individual
O	503	511	opinions
O	512	516	have
O	517	522	often
O	523	529	guided
O	530	538	practice
O	539	541	in
O	542	546	this
O	547	552	field
O	552	553	.

O	554	557	The
O	558	565	present
O	566	571	study
O	572	575	had
O	576	577	2
O	578	586	purposes
O	586	587	.

O	588	590	To
O	591	599	evaluate
O	600	607	whether
O	608	611	the
O	612	615	use
O	616	618	of
O	619	627	aluminum
O	627	628	-
O	628	633	based
O	634	648	antiperspirant
O	649	654	while
O	655	664	receiving
O	665	673	external
O	674	678	beam
O	679	691	radiotherapy
O	692	695	for
O	696	701	stage
O	702	703	0
O	703	704	,
O	705	706	I
O	706	707	,
O	708	710	or
O	711	713	II
O	714	720	breast
O	721	727	cancer
O	728	732	will
O	733	741	increase
O	742	748	axilla
O	749	753	skin
O	754	762	toxicity
O	763	766	and
O	767	769	to
O	770	778	evaluate
O	779	786	whether
O	787	790	the
O	791	794	use
O	795	797	of
O	798	812	antiperspirant
O	813	819	during
O	820	828	external
O	829	833	beam
O	834	846	radiotherapy
O	847	855	improves
O	856	863	quality
O	864	866	of
O	867	871	life
O	871	872	.

O	873	874	A
O	875	880	total
O	881	883	of
B-total-participants	884	887	198
O	888	900	participants
O	901	905	were
O	906	916	randomized
O	917	919	to
O	920	926	either
O	927	930	the
O	931	943	experimental
O	944	949	group
O	950	951	(
O	951	965	antiperspirant
O	965	966	)
O	967	969	or
B-control	970	977	control
I-control	978	983	group
I-control	984	985	(
I-control	985	993	standard
I-control	994	998	care
I-control	998	999	-
I-control	999	1003	wash
I-control	1004	1008	only
I-control	1008	1009	)
O	1009	1010	.

O	1011	1014	The
O	1015	1019	skin
O	1020	1029	reactions
O	1030	1032	in
O	1033	1037	both
O	1038	1044	groups
O	1045	1049	were
O	1050	1058	measured
O	1059	1065	weekly
O	1066	1069	and
O	1070	1071	2
O	1072	1077	weeks
O	1078	1083	after
O	1084	1093	treatment
O	1094	1099	using
O	1100	1103	the
O	1104	1112	National
O	1113	1119	Cancer
O	1120	1129	Institute
O	1130	1136	Common
O	1137	1145	Toxicity
O	1146	1154	Criteria
O	1155	1162	Adverse
O	1163	1169	Events
O	1169	1170	,
O	1171	1178	version
O	1179	1180	3
O	1180	1181	,
O	1182	1190	toxicity
O	1191	1198	grading
O	1199	1207	criteria
O	1207	1208	.

O	1209	1213	Both
O	1214	1220	groups
O	1221	1230	completed
O	1231	1234	the
O	1235	1245	Functional
O	1246	1256	Assessment
O	1257	1260	for
O	1261	1268	Chronic
O	1269	1276	Illness
O	1277	1284	Therapy
O	1284	1285	'
O	1285	1286	s
O	1287	1300	questionnaire
O	1301	1304	for
O	1305	1308	the
O	1309	1315	breast
O	1316	1326	population
O	1327	1334	quality
O	1335	1337	of
O	1338	1342	life
O	1343	1353	assessment
O	1354	1358	tool
O	1358	1359	,
O	1360	1364	with
O	1365	1375	additional
O	1376	1385	questions
O	1386	1396	evaluating
O	1397	1400	the
O	1401	1407	effect
O	1408	1410	of
O	1411	1419	underarm
O	1420	1434	antiperspirant
O	1435	1438	use
O	1439	1441	on
O	1442	1449	quality
O	1450	1452	of
O	1453	1457	life
O	1458	1464	before
O	1465	1474	treatment
O	1474	1475	,
O	1476	1487	immediately
O	1488	1493	after
O	1494	1503	treatment
O	1503	1504	,
O	1505	1508	and
O	1509	1510	2
O	1511	1516	weeks
O	1517	1522	after
O	1523	1532	treatment
O	1533	1539	during
O	1540	1543	the
O	1544	1549	study
O	1549	1550	.

O	1551	1554	The
O	1555	1559	skin
O	1560	1568	reaction
O	1569	1573	data
O	1574	1578	were
O	1579	1587	analyzed
O	1588	1593	using
O	1594	1597	the
O	1598	1609	generalized
O	1610	1620	estimating
O	1621	1629	equation
O	1629	1630	.

O	1631	1633	No
O	1634	1647	statistically
O	1648	1659	significant
O	1660	1670	difference
O	1671	1674	was
O	1675	1679	seen
O	1680	1682	in
O	1683	1686	the
B-outcome	1687	1691	skin
I-outcome	1692	1700	reaction
O	1701	1708	between
O	1709	1712	the
O	1713	1714	2
O	1715	1721	groups
O	1722	1726	over
O	1727	1731	time
O	1731	1732	.

O	1733	1736	The
B-outcome	1737	1744	quality
I-outcome	1745	1747	of
I-outcome	1748	1752	life
O	1753	1757	data
O	1758	1762	also
O	1763	1771	revealed
O	1772	1774	no
O	1775	1788	statistically
O	1789	1800	significant
O	1801	1811	difference
O	1812	1819	between
O	1820	1823	the
O	1824	1825	2
O	1826	1832	groups
O	1833	1837	over
O	1838	1842	time
O	1842	1843	.

O	1844	1848	Data
O	1849	1857	analysis
O	1858	1867	indicates
O	1868	1872	that
O	1873	1878	using
O	1879	1893	antiperspirant
O	1894	1903	routinely
O	1904	1910	during
O	1911	1919	external
O	1920	1924	beam
O	1925	1937	radiotherapy
O	1938	1941	for
O	1942	1947	Stage
O	1948	1949	0
O	1949	1950	,
O	1951	1952	I
O	1952	1953	,
O	1954	1956	or
O	1957	1959	II
O	1960	1966	breast
O	1967	1973	cancer
O	1974	1978	does
O	1979	1982	not
O	1983	1989	affect
O	1990	1993	the
O	1994	2003	intensity
O	2004	2006	of
O	2007	2010	the
O	2011	2015	skin
O	2016	2024	reaction
O	2025	2027	or
O	2028	2031	the
O	2032	2036	self
O	2036	2037	-
O	2037	2045	reported
O	2046	2053	quality
O	2054	2056	of
O	2057	2061	life
O	2061	2062	.

O	2063	2067	This
O	2068	2076	evidence
O	2077	2085	supports
O	2086	2090	that
O	2091	2093	in
O	2094	2098	this
O	2099	2109	particular
O	2110	2120	population
O	2120	2121	,
O	2122	2127	there
O	2128	2130	is
O	2131	2133	no
O	2134	2141	purpose
O	2142	2144	to
O	2145	2153	restrict
O	2154	2159	these
O	2160	2165	women
O	2166	2170	from
O	2171	2176	using
O	2177	2192	antiperspirants
O	2193	2199	during
O	2200	2205	their
O	2206	2215	treatment
O	2215	2216	,
O	2217	2220	and
O	2221	2224	the
O	2225	2233	decision
O	2234	2236	to
O	2237	2240	use
O	2241	2243	an
O	2244	2258	antiperspirant
O	2259	2261	or
O	2262	2265	not
O	2266	2268	in
O	2269	2273	this
O	2274	2281	setting
O	2282	2288	should
O	2289	2291	be
O	2292	2296	left
O	2297	2299	to
O	2300	2303	the
O	2304	2314	discretion
O	2315	2317	of
O	2318	2321	the
O	2322	2329	patient
O	2329	2330	.
